

 Open access • Posted Content • DOI:10.1101/454397

## **In vitro model of inflammatory, hypoxia, and cancer stem cell signaling in pancreatic cancer using heterocellular 3-dimensional spheroids** — [Source link](#)

Megha Suresh, George Mattheolabakis, George Mattheolabakis, Amit Singh ...+1 more authors

**Institutions:** Northeastern University, University of Louisiana at Monroe

**Published on:** 26 Oct 2018 - bioRxiv (Cold Spring Harbor Laboratory)

**Topics:** Cancer stem cell, Tumor microenvironment, Pancreatic cancer, Stem cell marker and Cancer cell

Related papers:

- [Pancreatic tumor microenvironment confers highly malignant properties on pancreatic cancer cells.](#)
- [Improved Methods to Generate Spheroid Cultures from Tumor Cells, Tumor Cells & Fibroblasts or Tumor-Fragments: Microenvironment, Microvesicles and MiRNA.](#)
- [The role of CD44 and cancer stem cells](#)
- [Notch pathway is involved in the suppression of colorectal cancer by embryonic stem cell microenvironment.](#)
- [3D printed in vitro tumor tissue model of colorectal cancer.](#)

Share this paper:    

View more about this paper here: <https://typeset.io/papers/in-vitro-model-of-inflammatory-hypoxia-and-cancer-stem-cell-2r76snh5po>

1                   ***In vitro* model of inflammatory, hypoxia, and cancer**  
2                   **stem cell signaling in pancreatic cancer using**  
3                   **heterocellular 3-dimensional spheroids**

4  
5                   **Megha Suresh<sup>1</sup>, George Mattheolabakis<sup>1,2</sup>, Amit Singh<sup>3</sup>, and Mansoor Amiji<sup>1</sup>**

6                   <sup>1</sup>Department of Pharmaceutical Sciences, School of Pharmacy,  
7                   Northeastern University, Boston, Massachusetts

8                   <sup>2</sup>Department of Basic Pharmaceutical Sciences, School of Pharmacy,  
9                   University of Louisiana at Monroe, Monroe, Louisiana

10                   <sup>3</sup>AllExcel, Inc., 135 Wood St, West Haven, Connecticut

11  
12  
13  
14  
15                   *Running Title: In vitro* co-culture spheroid model of pancreatic cancer

16  
17                   *Conflict of Interests:* The authors declare that they have no conflicts of interest.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42                   \*Corresponding author:

43                   Tel. (617) 373-3137

44                   Fax (617) 373-8886

45                   Email: [m.amiji@northeastern.edu](mailto:m.amiji@northeastern.edu)

## 46 Abstract

47 **Introduction:** As one of the most aggressive cancers worldwide, pancreatic cancer is associated  
48 with an extremely poor prognosis. The pancreatic tumor microenvironment consists of cancer cells  
49 and other tumor associated cells. Cross-talk between these different cell types through various  
50 signaling molecules results in the development of a more aggressive and malignant phenotype.  
51 Additionally, due to the highly dysregulated vasculature of tumors, the inner tumor core becomes  
52 hypoxic and eventually necrotic. Therefore, there is a need for the development of a  
53 physiologically relevant *in vitro* model that recapitulates these dynamic cell-cell interactions and  
54 the 3-dimensional (3D) structure of pancreatic tumors.

55 **Methods:** Four different 3D co-culture spheroid models using different combinations of Panc-1  
56 tumor cells, J774.A1 macrophages, and NIH-3T3 fibroblast cell lines were reproducibly developed  
57 using the hanging drop technique in order to mimic the tumor microenvironment and to evaluate  
58 the differences in expression of various inflammatory, hypoxia, and cancer stem cell markers,  
59 including IL-8, TNF- $\alpha$ , TGF- $\beta$ , HIF-1 $\alpha$ , HIF-2 $\alpha$ , SCF, and LDH-A. Additionally,  
60 immunofluorescence studies were employed to investigate whether these spheroids tested positive  
61 for a cancer stem cell population.

62 **Results:** Pronounced differences in morphology as well as expression of signalling markers were  
63 observed using qPCR, indicative of strong influences of co-culturing different cell lines. These  
64 models also tested positive for cancer stem cell (CSCs) markers based on immunofluorescence  
65 and qPCR analysis.

66 **Conclusion:** Our results demonstrate the potential of 3D co-culture spheroid models to capture  
67 the inflammatory and hypoxic markers of pancreatic tumor microenvironment. We further  
68 demonstrate the presence of cancer cells with stem cell markers, similar to actual pancreatic cancer  
69 tumor. These spheroids present excellent *in vitro* system to study tumor-immune-stromal cell  
70 interactions as well as test deliverability of potential therapeutics in the tumor microenvironment  
71 with accurate physical and physiological barriers.

72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88

89 **Keywords:** Hetero-cellular 3D spheroids, *in vitro* model, pancreatic cancer, inflammation,  
90 hypoxia, cancer stem cells (CSCs), immunofluorescence, qPCR

## 91 **1. Introduction**

92 Pancreatic cancer is one of the deadliest cancers associated with the 4<sup>th</sup> highest number of  
93 deaths amongst all cancers worldwide, with the incidence rate nearly equaling the mortality rate.  
94 In 2018, it is estimated that 55,440 adults will be diagnosed with pancreatic cancer and 44,330  
95 patients will die of the disease (1). With the growing epidemic of type I diabetes worldwide, the  
96 number of patients with pancreatic cancer is expected to increase significantly in the coming years.  
97 Despite tremendous efforts to improve patient survival, including surgical resection,  
98 chemotherapy, and radiation therapy, these options have not been successful in prolonging patient  
99 life beyond a few months in pancreatic cancer (1-5). The poor prognosis in pancreatic cancer  
100 patient is largely associated with late presentation of the symptoms when the disease has already  
101 progressed to advanced stage where significant metastasis has occurred combined with lack of  
102 effective therapies that can improve patient outcomes. Additionally, there is a need to develop  
103 suitable *in vitro* and *in vivo* disease models that can improve the drug development process.

104 The pancreatic tumor microenvironment is represented by an outer proliferative and inner  
105 necrotic zone, along with stromal components including the extra-cellular matrix, blood vessels,  
106 signaling molecules, and other cells including tumor-associated macrophages (TAMs), tumor-  
107 associated fibroblasts (TAFs), and endothelial cells form (6, 7). Animal models for pancreatic  
108 cancer recapitulate the tumor microenvironment to some extent but are difficult to develop, time  
109 consuming and very expensive (8). Two dimensional (2D) cell monolayers are simple to culture  
110 and provide convenient testing platforms for screening anti-cancer drugs but they are not truly  
111 representative of the tumor microenvironment, morphologically or functionally (9). More recent  
112 efforts have shifted focus on three dimensional (3D) co-culture spheroids that serve as a robust *in*  
113 *vitro* model that exhibit several features of pancreatic cancer microenvironment (10).

114           Within a 3D environment, cancer cells can switch to a stem cell like phenotype, which is  
115 more aggressive, metastatic and shows higher resistance to chemotherapy. Additionally, these  
116 cancer stem cells or CSCs are pluripotent, repair damaged cells and show self-renewal  
117 characteristics. In other words, a CSC can divide to form one daughter CSC and one non-tumor  
118 initiating cell. However, it is unclear where these CSCs originate from, if tumor cells develop into  
119 CSCs or if they are formed from stem cells. These cells are characterized by various markers, such  
120 as stem cell factor (SCF), epithelial surface antigen (ESA), CD24, CD44 and CD133 (11-13).

121           Hypoxia regulates tumor cell phenotype and cancer cells adapt their metabolism to sustain  
122 their growth, unlike healthy cells that are severely damaged in hypoxic conditions. Cancer cells  
123 can also undergo genetic mutations under hypoxia to give rise to multi-drug resistance (MDR),  
124 enhanced angiogenesis and migration. Cancer stem cells regulate their microenvironments to form  
125 niches, within which they reside. CSCs, in fact, prefer hypoxic environments because they avoid  
126 DNA damage from reactive oxygen species at higher oxygen levels. Under low oxygen conditions,  
127 levels of hypoxia inducible factors, HIF1 $\alpha$  and HIF2 $\alpha$  are elevated. However, CSCs tend to up-  
128 regulate HIF2 $\alpha$  levels regardless of oxygen levels, to induce an artificial hypoxic environment  
129 within which they thrive, sustain their self-renewal properties and maintain their undifferentiated  
130 state (14-19).

131           The dynamic interplay among cancer, stromal and immune cells occurs through various  
132 cytokines and chemokines. Numerous signaling pathways and transcription factors, including NF-  
133  $\kappa$ B, Snail and Slug, drive CSC formation as well as epithelial-mesenchymal transition (EMT). IL-  
134 6, TNF- $\alpha$  and IL-1 $\beta$  bring about HIF-1 $\alpha$  release, activating the NF- $\kappa$ B pathway, which ultimately  
135 leads to the down-regulation of apoptotic genes. Snail and Slug are also activated, regulating E-  
136 cadherin levels, thereby driving EMT (20-22). Sonic hedgehog (Shh) pathway activation, induced

137 by TNF- $\alpha$ , leads to increased tumor cell proliferation through Snail and other EMT regulators (23,  
138 24). Activation of the tumor suppressor gene p53 causes high mobility group box 1 (HMGB1)  
139 release, leading to TNF- $\alpha$  release from neighboring immune cells, inducing NF- $\kappa$ B and Snail  
140 activation (25, 26). This leads to activation of CXCL1, which attracts myeloid cells towards the  
141 tumor, further facilitating EMT (27). Inhibition of NF- $\kappa$ B decreases EMT and proliferation rates  
142 of CSCs (23).

143 Transforming growth factor-beta (TGF- $\beta$ ), an EMT regulator, recruits immune cells to the  
144 tumor microenvironment, which then release pro-inflammatory cytokines, including tumor  
145 necrosis factor-alpha (TNF- $\alpha$ ). With TNF- $\alpha$  also increasing TGF- $\beta$  levels, a positive feedback loop  
146 is created (26, 28, 29). However, the CSCs themselves efficiently regulate the inflammatory state  
147 by releasing interleukin-8 (IL-8), MCP-1 and RANTES and bring about stromal cell proliferation  
148 and inflammation (30).

149 We have developed a single cell (homocellular) and 3-in-1 heterocellular spheroid model  
150 formed by self-association of Panc-1 human pancreatic adenocarcinoma cells, J774.A1 murine  
151 macrophages and NIH/3T3 murine fibroblasts that better recapitulate the 3D component as well  
152 as the cell-to-cell cross-talk in the microenvironment of avascularized tumors in early stages of  
153 growth. They also mimic the hypoxic gradient from the periphery to the core of the tumor (31).  
154 Therefore, they are crucial in helping gain a deeper insight into tumor biology as well as serve as  
155 an efficacious platform for testing of anti-neoplastic agents, thereby providing higher odds of  
156 success in *in vivo* testing of agents (32).

157

## 158 **2. Materials and Methods**

### 159 **2.1. Cell lines and culture conditions**

160 The cell lines used in this study include the human pancreatic epithelioid carcinoma - Panc-  
161 1 cell line, the J774-A1 murine macrophage cell line and the NIH/3T3 murine fibroblast cell line.  
162 All cell lines were obtained from American Type Culture Collection (ATCC, Manassas, VA).  
163 Panc-1 and J774.A1 cells were grown in 1X Dulbecco's Modified Eagle's Medium (DMEM) with  
164 4.5g glucose and L-glutamine without sodium pyruvate obtained from Corning Cellgro (Manassas,  
165 VA). The growth medium was supplemented with 10% fetal bovine serum and 1% penicillin-  
166 streptomycin. NIH/3T3 cell line was grown in 1X DMEM supplemented with 10% fetal calf serum  
167 and 1% penicillin-streptomycin. All cell lines were cultured at 37°C at 5% CO<sub>2</sub>.

168

## 169 **2.2. Establishment of homocellular and heterocellular 3D tumor spheroids**

170 For the spheroid development, 96-well hanging drop plates from 3D-Biomatrix were used  
171 to grow single cell (i.e., homocellular) and multiple cell (i.e., heterocellular) spheroids. The  
172 spheroids were generated using 40µl of cell suspensions containing 20,000 cells in each well. For  
173 the homocellular spheroids, 20,000 Panc-1 cells were seeded in each well. For the Panc-1: J774.A1  
174 and for the Panc-1: NIH/3T3 heterocellular spheroids, a 40 µl mixture of 10,000 tumor cells and  
175 10,000 immune/stromal cells were seeded in each well. For the Panc-1: J774.A1: NIH/3T3  
176 spheroids, a cell suspension mixture containing a 1:1:1 ratio of cell numbers with a total of 20,000  
177 cells per well were seeded. We cultured spheroids for 5 days post-seeding and harvested them for  
178 downstream analyses. In order to maintain humidity in the spheroid plates, sterile 1X PBS was  
179 added to the in-built reservoirs on the 3<sup>rd</sup> day of growth.

180 To measure the size of these spheroids, they were washed with 1X PBS upon harvesting,  
181 fixed with 4% Formalin and mounted on microscope depression slides (Fisher Scientific, PA)  
182 using the Shandon Immu-Mount (Thermo Scientific, PA), and covered with a cover-slip. The Carl  
183 Zeiss LSM 700 confocal microscope was used to capture images of spheroids and the Image J

184 software was then used to measure and record the diameter. 5 $\mu$ m optical slices of spheroids were  
185 imaged through Z stacking on the confocal microscope and the total number of slices per spheroid  
186 was determined. This information was then used to calculate and record spheroid depth.

### 187 188 **2.3 Distribution of Panc-1, J774.A1 and NIH3T3 cells within the heterocellular spheroids**

189 In order to assess the arrangement of different cell types within the 1:1:1 heterocellular  
190 spheroid, Panc-1, J774.A1 and NIH3T3 cells were stained with Cellbrite Blue Cytoplasmic  
191 Membrane Labeling Kit, Cellbrite Green and Cellbrite Red Cytoplasmic Membrane Labeling Dye  
192 (Biotium, CA), respectively. 1X PBS was used to wash off the excessive dye, and the cells were  
193 re-suspended in 1X DMEM, counted and seeded to form spheroids using the method described in  
194 2.2.

195 The spheroids were harvested on day 5 of growth, washed with 1X PBS, fixed with 4%  
196 formalin and mounted on a microscope depression slide using Shandon Immu-Mount. The slides  
197 were protected with a cover slip and fluorescent images were captured using the confocal  
198 microscope.

### 199 200 **2.4. qPCR analysis of inflammatory, hypoxia and cancer stem cell signaling in spheroids**

201 To assess the levels of various inflammatory, hypoxia and cancer stem cell markers, total  
202 RNA from homocellular and heterocellular spheroids was extracted using the Quick-RNA™  
203 MiniPrep RNA extraction kit (Zymo Research, CA). The NanoDrop (Thermo Scientific,  
204 Willington, DE) was used to measure and record RNA concentrations. 1 $\mu$ g of total RNA were used  
205 for cDNA synthesis using the Verso cDNA synthesis Kit (Thermo Scientific, PA).

206 RT-PCR was used for the evaluation of inflammatory markers: IL-8, TNF- $\alpha$ , TGF- $\beta$ . The  
207 Platinum PCR SuperMix (Life Technologies, NY) was used and both human and mouse primers,



208 as shown in table 1, were used in order to ensure specie specific amplification with  $\beta$ -actin as the  
209 housekeeping control. The PCR products were run on a 2% Agarose E-Gel with SYBR Safe (Life  
210 Technologies, NY). The ChemiDoc™ XRS imaging system (Bio-Rad, Hercules, CA) was used  
211 to image the bands. The intensity of the bands obtained for human IL-8, TNF- $\alpha$  and TGF- $\beta$  were  
212 expressed as a percentage of the human  $\beta$ -actin band intensity for the respective samples.  
213 Similarly, the intensity of the bands obtained for the murine genes of IL-8, TNF- $\alpha$  and TGF- $\beta$  were  
214 expressed as a percentage of the murine  $\beta$ -actin band intensity for each sample.

215 To evaluate levels of hypoxia markers: LDH-A, HIF-1 $\alpha$ , HIF-2 $\alpha$ , and cancer stem cell  
216 marker: SCF in normoxic cells, hypoxic cells, homocellular and heterocellular spheroids, the  
217 LightCycler® 480 SYBR Green I Master kit (Roche Diagnostics, Indianapolis, IN) was used to  
218 carry out qPCR along with the Roche Light Cycler 480 machine. The primers used are listed in  
219 Table 2. Beta-actin was used as the housekeeping control,  $\Delta$ Ct values were obtained by calculating  
220 the difference between the Ct values of the target gene and beta actin of each sample and the 2<sup>-</sup>  
221  $\Delta$ CT method of analysis was used to determine % gene expression.

222

## 223 **2.5. Analysis of CD24+ and stem cell factor expression in spheroids**

224 Spheroids harvested from hanging drop plates 5 days post-seeding were transferred to a  
225 96-well Polystyrene assay plate (Corning Incorporated, NY) and 0.2ml Cell Staining buffer  
226 (BioLegend, CA) was added to each well to prevent receptor internalization. This was followed  
227 by fixation with 4% formalin. Spheroids were then washed twice with ice cold PBS, and blocking  
228 was carried out using a 10% FBS in PBS solution at room temperature for 30 minutes.

229 Spheroids were incubated for 10 hours with FITC mouse anti-human CD24 (BD  
230 Pharmingen, CA, catalog no. 55524, clone ML5) antibody or the rabbit polyclonal anti-human  
231 SCF primary antibody (Thermo Scientific, PA, catalog no. PA511563) in 2% BSA (bovine serum

232 albumin, Fisher, PA) in 1X PBS. The SCF-stained spheroids were then incubated with a goat Anti-  
233 Rabbit IgG DyLite 594 conjugated highly cross adsorbed antibody diluted in 2% BSA in 1X PBS  
234 for 2 hours. All spheroids were then washed, and incubated with Hoechst 33342 Dye (Life  
235 Technologies, PA) to stain the nucleus, washed and imaged using the confocal microscope.

236

### 237 **3. Results and Discussion**

238 Spheroids were successfully grown using the 96-well hanging drop plates. The Panc-1  
239 homocellular spheroids were the largest with a mean diameter of 919 $\mu$ m and an average thickness  
240 of 135 $\mu$ m, with a spherical morphology. The Panc-1:J774.A1 heterocellular spheroids were  
241 loosely formed spheroids with a mean diameter of 745  $\mu$ m and an average thickness of 60 $\mu$ m and  
242 were also observed to be non-uniform in shape. The Panc-1:NIH/3T3 heterocellular spheroids  
243 were irregularly shaped with a mean diameter of 919.51 $\mu$ m and an average thickness of 116  $\mu$ m,  
244 and the 3-in-1 heterocellular spheroids with a mean diameter of 396  $\mu$ m and an average thickness  
245 of 55  $\mu$ m formed the smallest and densest spheroids. The size and morphology of all four spheroid  
246 models is shown in Figure 1.

247 We stained the three individual cell types in 3-in-1 heterocellular spheroids with specific  
248 stains to understand their natural arrangement within the spheroids. As shown in Figure 2, Panc-1  
249 cells were stained blue, J774.A1 cells in green and NIH/3T3 cells were stained in red. As evident  
250 from the images, no specific arrangement of the three cell lines was observed within the 3-in-1  
251 heterocellular spheroid. This indicates that all cell types are in proximity of each other, which  
252 facilitates increased susceptibility to cross-talk through cytokine signaling. Giant cells were  
253 observed at the periphery of the spheroid. Since these were stained green, we hypothesize that  
254 these were formed by fusion of the macrophages. Molberg *et. al* carried out histological and  
255 immune-histochemical studies on ten pancreatic neoplasms and observed osteoclast-like giant

256 cells in seven of these tumors. Their studies led them to conclude that the giant cells were  
257 histiocytic and non-neoplastic in origin (33). Multi-nucleated foreign body giant cells formed as a  
258 result of fusion of macrophages have been noted in thyroid, breast, skin and hepatic carcinomas as  
259 well, presumably drawn to the tumors in response to chemotactic factors and cytokines (34-37).  
260 However, immunocytochemical experiments employing epithelial, histiocytic and endothelial  
261 markers are required to confirm this hypothesis.

262         Next, we studied the expression of inflammatory, hypoxia and stem cell markers across  
263 different monolayer and spheroid models in order to assess the contribution of and interaction  
264 between different cell types in modulating the microenvironment. Analysis of inflammatory  
265 marker expression through RT-PCR and gel electrophoresis revealed distinct expression profiles  
266 across the spheroid models themselves and when compared to cells grown in normoxic and  
267 hypoxic conditions. Marker levels were expressed as a percentage of beta actin in the respective  
268 samples. IL-8 has been known to drive tumor metastasis, proliferation and survival and tumor cells  
269 undergoing EMT secrete increased levels of the pro-inflammatory cytokine (38). Additionally,  
270 senescent TAFs known to be up-regulated in pancreatic tumor microenvironments and TAMs  
271 secrete IL8 (39, 40). Highest levels of IL-8 (Figure 3.a.) of about 27% were seen in the 3-in-1  
272 heterocellular spheroid followed 21.43% in the Panc-1:J774.A1 spheroid. Comparatively low  
273 levels (20.8%) were seen in the Panc-1 homocellular spheroid followed by 18% in the Panc-  
274 1:NIH/3T3 spheroid. Numerous sources cite the role of TNF- $\alpha$  in the pancreatic tumors to be that  
275 of a double-edged sword, due to both, its pro and anti-tumorigenic effects. TNF- $\alpha$  levels are  
276 significantly elevated in pancreatic tumors and since they are primarily produced primarily by  
277 TAMs, the trend seen in the spheroid models was not surprising (41). Highest levels of TNF- $\alpha$  at  
278 13% was observed in Panc-1:J774.A1 spheroid (Fig 3.b.). This was followed by comparatively

279 low levels of 4%, 2.5% and 5% in the Panc-1 homocellular spheroid, Panc-1:NIH/3T3 spheroid  
280 and the 3-in-1 heterocellular spheroid respectively. Similarly, TGF- $\beta$  has anti-tumorigenic effects  
281 at the early stages of tumor growth but at latter stages promotes tumor cell proliferation,  
282 desmoplasia and metastasis (42). Since TGF- $\beta$  is produced by both tumor and stromal cells, the  
283 trend seen across spheroid models in our PCR experiment agreed with expected results (43).  
284 Highest levels of TGF- $\beta$  (Figure 3.c.) of 56% were observed in the Panc-1:NIH/3T3 spheroid  
285 followed by 42% in the Panc-1 homocellular spheroid. It is interesting to note here that the Panc-  
286 1:NIH/3T3 spheroids were among the largest and densest, suggesting a morphological as well as  
287 a phenotypic relevance. Low levels of 26% and 18% were observed in the Panc-1:J774.A1 and 3-  
288 in-1 heterocellular spheroid, respectively. Although none of these results were statistically  
289 significant, the trends of their expression across different spheroid models are representative of the  
290 contribution of the different cell types.

291 TAMs and tumor cells under hypoxic conditions employ the glycolytic pathway and up-  
292 regulate HIF-1 $\alpha$  (41). Analysis of qPCR results for HIF-1 $\alpha$  revealed highest levels of expression  
293 in the Panc-1:J774.A1 spheroid at 1.5% compared to Panc-1 cells grown in normoxic conditions  
294 followed by that in the 3-in-1 heterocellular spheroids at 0.94% increase. Both results were  
295 statistically significant. p-Values were calculated using 1 way ANOVA and comparing values of  
296 spheroids with those in normoxic cells and tested at a significance level of  $\alpha = 0.05$ . These results  
297 strongly correlate with the expected phenotype observed in pancreatic tumor microenvironments  
298 (41). The Panc-1:NIH/3T3 spheroid expressed HIF-1 $\alpha$  at 0.43% and the Panc-1 homocellular  
299 spheroid at 0.27%. However the result for the Panc-1:NIH/3T3 spheroid and the Panc-1  
300 homocellular spheroid did not reach statistical significance.

301           Due to increased hypoxia and glycolytic metabolism due to the Warburg effect, there is an  
302 associated low pH tumor microenvironment and an increase in HIF-2 $\alpha$  expression (44). This  
303 increased expression is associated with dense stroma and so we hypothesized that the fibroblast  
304 containing spheroids may exhibit hypoxia like molecular feature. Indeed, qPCR analysis of HIF-  
305 2 $\alpha$  level (Figure 4.b.) reveals highest levels of 147% in the Panc-1:NIH/3T3 spheroid followed by  
306 15% in the 3-in-1 heterocellular spheroid (45). Both results were found to be statistically  
307 significant. Third highest HIF-2 $\alpha$  levels were observed in the Panc-1:J774.A1 spheroid at 8.95%.  
308 Levels in normoxic and hypoxic monolayers were 6.27% and 5.15% and at 4.34% in the Panc-1  
309 homocellular spheroids. These results assert that the multicellular spheroids are able to recapitulate  
310 the hypoxic microenvironment of a tumor, which is a hallmark property of cancer.

311           LDH-A levels were highest in the normoxic Panc-1 cells, as shown in Figure 4.c., at 255%,  
312 followed by 178% and 113% in hypoxic cells and the 3-in-1 heterocellular spheroid, respectively.  
313 Although we would have expected to see highest levels of LDH-A in hypoxic Panc-1 cells, hypoxic  
314 cells very quickly revert their phenotype to normoxic when exposed even briefly to oxygen. Since  
315 these cells were withdrawn from the hypoxia chamber before processing PCR samples, the brief  
316 exposure to oxygen may have obfuscated results seen in the monolayer samples (46). It is however  
317 interesting to note that the highest levels among spheroids were seen in the densest 3-in-1  
318 heterocellular spheroid. The Panc-1 homocellular spheroid, Panc-1:NIH/3T3 spheroid and Panc-  
319 1:J774.A1 spheroid expression was 71%, 22% and 19% respectively. All results were found to be  
320 statistically significant. Binding of SCF to its ligand, c-kit, induces the up-regulation of HIF-1 $\alpha$   
321 through activation of PI3K/Akt and Ras/MEK/ERK pathways (47). Highest levels of SCF, shown  
322 in Figure 4.d., of 20% were seen in the Panc-1:J774.A1 spheroid, followed by 10% in the 3-in-1  
323 heterocellular spheroid. These results were found to be statistically significant. Next highest levels

324 were seen in the Panc-1:NIH/3T3 spheroid at 2.2%. Differences between SCF expression levels in  
325 the normoxic, hypoxic and homocellular spheroid were minimal and with no statistical  
326 significance. It is extremely interesting to note that correlation between HIF-1a and SCF  
327 expression across our models is suggestive of SCF induced HIF-1a upregulation. Immunostaining  
328 experiments for CD24 and SCF, both surface markers of cancer stem cells (CSCs), and subsequent  
329 imaging of fluorescence using the confocal microscope revealed presence of CSCs in Panc-1  
330 homocellular, Panc-1:J774.A1 and the 3-in-1 heterocellular spheroid, shown in Figures 5 and 6.  
331 Detection of stem cell populations in these spheroid models through immunofluorescence along  
332 with the trends seen in inflammatory and hypoxia markers through qPCR further support our  
333 argument for using co-culture spheroid models as physiologically relevant testing platforms for  
334 anti-cancer therapies.

335

#### 336 **4. Conclusions**

337 The hanging drop method was used to successfully and reproducibly generate all four self-  
338 aggregating spheroid models, which were then characterized for their morphology and size.  
339 Pancreatic tumors are known to have a desmoplastic stroma, which not only provides structural  
340 support for the tumor as well as nutrients for the tumor cell proliferation, but also obstructs  
341 chemotherapeutics from reaching the tumor core. The random arrangement of cells in 3 in 1  
342 heterocellular spheroids were indicative of proximity of each cell line with the other, and increased  
343 cell-cell interaction, as seen in the tumor microenvironment. Additionally, this model has the  
344 smallest diameter and depth, further supporting our argument for a stronger resemblance of  
345 pancreatic tumor cells in their physiological state.

346           Although analysis of the inflammatory markers IL-8, TNF-a and TGF-b through PCR did  
347 not reveal statistically significant differences across spheroid models, the trends in the expression  
348 suggests that the microenvironment of these spheroids is conducive to desmoplasia, cell  
349 proliferation, EMT and metastasis.

350           Hypoxia drives angiogenesis and EMT, contributes to MDR and enables cancer cells to  
351 switch their metabolism to the anaerobic pathway. Analysis of glycolytic and cancer stem cell  
352 markers through qPCR revealed much greater differences in expression levels in the 3D model  
353 compared to Panc-1 cells monolayer cultures. Highest levels of HIF1-a and HIF-2a seen in the co-  
354 culture spheroids indicate a stronger hypoxic component in these models, within which cancer  
355 stem cells can maintain their state of self-renewal, and prevent damage from ROS.

356           CSCs are pluripotent, immortal and can modulate their phenotype based on environmental  
357 cues. They are also resistant to the action of conventional chemotherapy and can self-renew.  
358 Positive staining of CD24 and SCF surface markers through immunofluorescence is indicative of  
359 the presence of CSC within these spheroid models. SCF levels being significantly higher in the  
360 co-culture models, as evidenced in the PCR study, offer further support to the hypothesis that  
361 cancer stem cell formation is largely dependent on microenvironmental cells and cross-talk.

362           This model has the potential to replicate the barrier to drug delivery seen in tumors.  
363 Additionally, co-culturing of different cell types that form spheroids have shown significant effects  
364 in altering tumor phenotypes and influencing CSC population growth, thereby re-enforcing the  
365 need to develop robust and clinically relevant *in vitro* models for testing chemotherapeutic agents.

## 366 367 **Acknowledgements**

368           Financial support was provided by the National Cancer Institute of the National Institutes  
369 of Health through grant R21-CA213114.



## 370 References

- 371 1. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus  
372 gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:  
373 a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *Journal of*  
374 *clinical oncology : official journal of the American Society of Clinical Oncology.*  
375 2007;25(15):1960-6.
- 376 2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA: a cancer journal for*  
377 *clinicians.* 2013;63(1):11-30.
- 378 3. Winter JM, Brennan MF, Tang LH, D'Angelica MI, Dematteo RP, Fong Y, et al. Survival  
379 after resection of pancreatic adenocarcinoma: results from a single institution over three  
380 decades. *Annals of surgical oncology.* 2012;19(1):169-75.
- 381 4. Michl P, Gress TM. Current concepts and novel targets in advanced pancreatic cancer. *Gut.*  
382 2013;62(2):317-26.
- 383 5. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al.  
384 FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *The New England*  
385 *journal of medicine.* 2011;364(19):1817-25.
- 386 6. Chiarugi P. Cancer-associated fibroblasts and macrophages: Friendly conspirators for  
387 malignancy. *Oncoimmunology.* 2013;2(9):e25563.
- 388 7. Wels J, Kaplan RN, Rafii S, Lyden D. Migratory neighbors and distant invaders: tumor-  
389 associated niche cells. *Genes & development.* 2008;22(5):559-74.
- 390 8. Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L. Mouse models of pancreatic cancer.  
391 *World journal of gastroenterology.* 2012;18(12):1286-94.
- 392 9. Tung YC, Hsiao AY, Allen SG, Torisawa YS, Ho M, Takayama S. High-throughput 3D  
393 spheroid culture and drug testing using a 384 hanging drop array. *The Analyst.*  
394 2011;136(3):473-8.
- 395 10. Sant S, Johnston PA. The production of 3D tumor spheroids for cancer drug discovery. *Drug*  
396 *discovery today Technologies.* 2017;23:27-36.
- 397 11. Soltysova A, Altanerova V, Altaner C. Cancer stem cells. *Neoplasma.* 2005;52(6):435-40.
- 398 12. Gaviraghi M, Tunici P, Valensin S, Rossi M, Giordano C, Magnoni L, et al. Pancreatic cancer  
399 spheres are more than just aggregates of stem marker-positive cells. *Bioscience reports.*  
400 2011;31(1):45-55.
- 401 13. Dongqing Wanga HZ, Ying Zhua, Yanfang Liub, Huiling Shenb, Ruigen Yina, Zhijian  
402 Zhangc, Zhaoliang Su. CD133+/CD44+/Oct4+/Nestin+ stem-like cells isolated from Panc-1  
403 cell line may contribute to multi-resistance and metastasis of pancreatic cancer. *Acta*  
404 *Histochemica.* 2013;115(4):349-56.
- 405 14. Li Z, Rich JN. Hypoxia and hypoxia inducible factors in cancer stem cell maintenance.  
406 *Current topics in microbiology and immunology.* 2010;345:21-30.
- 407 15. Warburg O. On the origin of cancer cells. *Science.* 1956;123(3191):309-14.
- 408 16. Bertout JA, Patel SA, Simon MC. The impact of O<sub>2</sub> availability on human cancer. *Nature*  
409 *reviews Cancer.* 2008;8(12):967-75.
- 410 17. Holmquist-Mengelbier L, Fredlund E, Lofstedt T, Noguera R, Navarro S, Nilsson H, et al.  
411 Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially  
412 regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. *Cancer cell.*  
413 2006;10(5):413-23.



- 414 18. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, et al. Hypoxia-inducible factors  
415 regulate tumorigenic capacity of glioma stem cells. *Cancer cell*. 2009;15(6):501-13.
- 416 19. Conrad PW, Freeman TL, Beitner-Johnson D, Millhorn DE. EPAS1 trans-activation during  
417 hypoxia requires p42/p44 MAPK. *The Journal of biological chemistry*. 1999;274(47):33709-  
418 13.
- 419 20. Shigdar S, Li Y, Bhattacharya S, O'Connor M, Pu C, Lin J, et al. Inflammation and cancer  
420 stem cells. *Cancer letters*. 2014;345(2):271-8.
- 421 21. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. *Molecular  
422 cancer research : MCR*. 2006;4(4):221-33.
- 423 22. Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, et al. Activation of an IL6  
424 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding  
425 the cancer stem cell population. *Molecular cell*. 2012;47(4):570-84.
- 426 23. Nakashima H, Nakamura M, Yamaguchi H, Yamanaka N, Akiyoshi T, Koga K, et al.  
427 Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic  
428 hedgehog induction in pancreatic cancer. *Cancer research*. 2006;66(14):7041-9.
- 429 24. Li SH, Fu J, Watkins DN, Srivastava RK, Shankar S. Sulforaphane regulates self-renewal of  
430 pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway.  
431 *Molecular and cellular biochemistry*. 2013;373(1-2):217-27.
- 432 25. Yan HX, Wu HP, Zhang HL, Ashton C, Tong C, Wu H, et al. p53 promotes inflammation-  
433 associated hepatocarcinogenesis by inducing HMGB1 release. *Journal of hepatology*.  
434 2013;59(4):762-8.
- 435 26. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. *Cell*.  
436 2010;140(6):883-99.
- 437 27. Schwitalla S, Ziegler PK, Horst D, Becker V, Kerle I, Begus-Nahrman Y, et al. Loss of p53  
438 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph  
439 node metastasis of carcinogen-induced colorectal tumors. *Cancer cell*. 2013;23(1):93-106.
- 440 28. Biele B, Moses HL. Transforming growth factor beta (TGF-beta) and inflammation in  
441 cancer. *Cytokine & growth factor reviews*. 2010;21(1):49-59.
- 442 29. Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity,  
443 clinical significance, and open questions. *Seminars in immunopathology*. 2013;35(5):585-  
444 600.
- 445 30. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Drug-selected human lung  
446 cancer stem cells: cytokine network, tumorigenic and metastatic properties. *PloS one*.  
447 2008;3(8):e3077.
- 448 31. Mueller-Klieser W. Multicellular spheroids. *J Cancer Res Clin Oncol*. 1987;113(2):101-22.
- 449 32. Kim JB. Three-dimensional tissue culture models in cancer biology. *Seminars in cancer  
450 biology*. 2005;15(5):365-77.
- 451 33. Molberg KH, Heffess C, Delgado R, Albores-Saavedra J. Undifferentiated carcinoma with  
452 osteoclast-like giant cells of the pancreas and periampullary region. *Cancer*.  
453 1998;82(7):1279-87.
- 454 34. Athanasou NA, Wells CA, Quinn J, Ferguson DP, Heryet A, McGee JO. The origin and  
455 nature of stromal osteoclast-like multinucleated giant cells in breast carcinoma: implications  
456 for tumour osteolysis and macrophage biology. *British journal of cancer*. 1989;59(4):491-8.
- 457 35. Silverberg SG, DeGiorgi LS. Osteoclastoma-like giant cell tumor of the thyroid. Report of a  
458 case with prolonged survival following partial excision and radiotherapy. *Cancer*.  
459 1973;31(3):621-5.

- 460 36. Andreev VC, Raitchev R, Nikolova D. Malignant Osteoclastoma of the Skin. The British  
461 journal of dermatology. 1964;76:40-4.
- 462 37. Hood DL, Bauer TW, Leibel SA, McMahon JT. Hepatic giant cell carcinoma. An  
463 ultrastructural and immunohistochemical study. American journal of clinical pathology.  
464 1990;93(1):111-6.
- 465 38. Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C. IL-8 signaling plays a  
466 critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer  
467 research. 2011;71(15):5296-306.
- 468 39. Wang T, Notta F, Navab R, Joseph J, Ibrahimov E, Xu J, et al. Senescent Carcinoma-  
469 Associated Fibroblasts Upregulate IL8 to Enhance Prometastatic Phenotypes. Molecular  
470 cancer research : MCR. 2017;15(1):3-14.
- 471 40. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clinical cancer research : an  
472 official journal of the American Association for Cancer Research. 2008;14(21):6735-41.
- 473 41. Penny HL, Sieow JL, Adriani G, Yeap WH, See Chi Ee P, San Luis B, et al. Warburg  
474 metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic  
475 ductal adenocarcinoma. Oncoimmunology. 2016;5(8):e1191731.
- 476 42. Principe DR, DeCant B, Mascarinas E, Wayne EA, Diaz AM, Akagi N, et al. TGFbeta  
477 Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune  
478 Evasion to Facilitate Tumorigenesis. Cancer research. 2016;76(9):2525-39.
- 479 43. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI, et al. Enhanced expression  
480 of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased  
481 survival. Gastroenterology. 1993;105(6):1846-56.
- 482 44. Chen R, Xu M, Nagati JS, Hogg RT, Das A, Gerard RD, et al. The acetate/ACSS2 switch  
483 regulates HIF-2 stress signaling in the tumor cell microenvironment. PloS one.  
484 2015;10(2):e0116515.
- 485 45. Zhang Q, Lou Y, Zhang J, Fu Q, Wei T, Sun X, et al. Hypoxia-inducible factor-2alpha  
486 promotes tumor progression and has crosstalk with Wnt/beta-catenin signaling in pancreatic  
487 cancer. Molecular cancer. 2017;16(1):119.
- 488 46. Maftouh M, Avan A, Sciarrillo R, Granchi C, Leon LG, Rani R, et al. Synergistic interaction  
489 of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in  
490 hypoxia. British journal of cancer. 2014;110(1):172-82.
- 491 47. Zhang M, Ma Q, Hu H, Zhang D, Li J, Ma G, et al. Stem cell factor/c-kit signaling enhances  
492 invasion of pancreatic cancer cells via HIF-1alpha under normoxic condition. Cancer letters.  
493 2011;303(2):108-17.

494  
495

496 **TABLES**

497

498 **Table 1.** Human and Mouse Primer sequences for IL8, TNF alpha, TGF beta and Beta actin

<b>Gene</b>	<b>Forward Primer</b>	<b>Reverse Primer</b>	<b>Annealing Temperature</b>	<b>Product Length</b>
Human IL8	CCACCGGAAGGA ACCATCTC	TTCCTTGGGGTCC AGACAGA	58.45°C	279
Human TNF alpha	CCCAGGCAGTCA GATCATCTTC	AGCTGCCCTCA GCTTGA	58.35°C	85
Human TGF beta	GGCAGTGGTTGA GCCGTGGA	TGTTGGACAGCT GCTCCACCT	60.55°C	531
Human Beta actin	CCTTTGCCGATC CGCCG	AACATGATCTGG GTCATCTTCTCGC	59.5°C	415
Mus musculus IL8	CACCTCAAGAAC ATCCAGAGCT	CAAGCAGAACTG AACTACCATCG	57.75°C	356
Mus musculus TNF alpha	GGCAGGTCTACT TTGGAGTCATTG C	ACATTGAGGCT CCAGTGAATTCG G	61.2°C	300
Mus musculus TGF beta	CGCCATCTATGA GAAAACC	GTAACGCCAGGA ATTGT	51.4°C	190
Mus musculus Beta actin	TGGAATCCTGTG GCATCCATGAAA C	TAAAACGCAGCT CAGTAACAGTCC G	59.6°C	349

499

500

501 **Table 2.** Human primer sequences for human HIF-1 $\alpha$ , HIF-1 $\beta$ , SCF, LDH-A and  $\beta$ -actin

<b>Gene</b>	<b>Forward Primer</b>	<b>Reverse Primer</b>	<b>Annealing Temperature</b>	<b>Product Length</b>
Human HIF-1 $\alpha$	GTGGTGGTTACT CAGCACTT	GGCTGTGTCGACT GAGGAAA	56.4°C	948
Human HIF-2 $\alpha$	CCTCCGACTCCT TCCGACT	CGAATCTCCTCAT GGTCGCA	58.45°C	817
Human SCF	GGATGACCTTGT GGAGTGCG	GCCCTTGTAAGAC TTGGCTG	58.45°C	417
Human LDH-A	TGGAGTGGAATG AATGTTGC	ATAGCCCAGGAT GTGTAGCC	55.4°C	155
Human Beta actin	CCTTTGCCGATC CGCCG	AACATGATCTGG GTCATCTTCTCGC	59.5°C	415

502

503

## 504 **FIGURE LEGENDS**

505

### 506 **Figure 1: Morphological assessment of spheroids**

507 A. Day 5 Panc-1 homocellular spheroid under 10X magnification - Average Diameter = 1365  
508 microns and Average Thickness = 193 microns; B. Day 5 1:1 Panc-1:J774.A1 heterocellular  
509 spheroid under 10X magnification - Average Diameter = 1039 microns and Thickness = 152  
510 microns; C. Day 5 1:1 Panc-1: NIH/3T3 heterocellular spheroid under 10X magnification -  
511 Average Diameter = 1327 microns and Thickness = 116 microns; D. Day 5 1:1:1 Panc-1: J774.A1:  
512 NIH3T3 heterocellular spheroid under 10X magnification - Average Diameter 371 microns and  
513 Average Thickness = 70 microns; E. Graphical analysis of spheroid diameter (n=3); F. Graphical  
514 analysis of the spheroid depth or thickness.

515

516

### 517 **Figure 2: Arrangement of different cell lines within 3-in-1 heterocellular spheroids**

518 A. Composite image showing distribution of Panc-1, J774.A1, NIH3T3 cells for the Day 5 1:1:1  
519 co-culture spheroid; B. Panc-1 cells stained with Cellbrite Blue; C. NIH/3T3 fibroblasts stained  
520 with Cellbrite Red; D. Brightfield image of heterocellular spheroid; E. J774.A1 macrophages  
521 stained with Cellbrite green.

522

523

### 524 **Figure 3. PCR evaluation of inflammatory markers in spheroid models**

525 A. Statistical evaluation of expression of the IL-8 gene; B. Statistical evaluation of expression of  
526 the TNF- $\alpha$  gene with 1-tailed test across all spheroid models. C. Statistical evaluation of expression  
527 of the TGF- $\beta$  gene. All expressions were normalized to the respective  $\beta$ -actin as housekeeping  
528 gene. The p values have been calculated to test differences compared to Panc-1 spheroids at  
529 significance limit of  $\alpha = 0.05$  using 1 way ANOVA.

530

531

### 532 **Figure 4: PCR evaluation of hypoxic and stem cell markers in spheroid models**

533 A. Relative expression of HIF1 $\alpha$  across different models. B. Relative expression of HIF-2 $\alpha$  across  
534 different models. C. Relative expression of LDH-A across different models. D. Relative expression  
535 of SCF across different models. The p values have been calculated using one way ANOVA to test  
536 differences compared to Panc-1 cells grown in normoxic conditions at significance limit of  $\alpha =$   
537 0.05

538

539

### 540 **Figure 5: Immunofluorescence study of CD24 expression in spheroid models**

541 i. CD24+ staining in Panc-1 Day 5 homocellular spheroids;  
542 ii. CD24+ staining in 1:1 Panc-1:J774.A1 Day 5 heterocellular spheroids;  
543 iii. CD24+ staining in 1:1:1 Panc-1:J774.A1:NIH3T3 Day 5 heterocellular spheroids

544

545

### 546 **Figure 6: Immunofluorescence study of SCF expression in spheroid models**

547 i. SCF staining in Panc-1 Day 5 homocellular spheroids;  
548 ii. SCF staining in 1:1 Panc-1:J774.A1 Day 5 heterocellular spheroids;  
549 iii. SCF staining in 1:1:1 Panc-1:J774.A1:NIH3T3 Day 5 heterocellular spheroids






Figure-1











Figure-2


3.a.

IL-8 Expression Across Spheroid Models



3.b.

TNF-a Expression Across Spheroid Models



3.c.

TGF-b Expression Across Spheroid Models






Figure-3




### HIF-1a Expression Across Spheroid Models



### HIF-2a expression across spheroid models



### LDH-a Expression Across Spheroid Models



### SCF Expression Across Spheroid Models







Figure-4




5.i.a. Hoechst Staining




5.i.b. FITC Staining




5.i.c. Bright field image




5.ii.a. Hoechst Staining




5.ii.b. FITC Staining




5.ii.c. Bright field image




5.iii.a. Hoechst Staining




5.iii.b. FITC Staining




5.iii.c. Bright field image




6.i.a. Hoechst Staining




6.i.b. DyLite Staining




6.i.c. Bright field image




6.ii.a. Hoechst Staining




6.ii.b. DyLite Staining




6.ii.c. Bright field image



6.iii.a. Hoechst Staining



6.iii.b. DyLite Staining



6.iii.c. Bright field image